Item 5.02. Departure of Directors or Certain Officers;
Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
On September 8, 2021, Catalyst Biosciences, Inc. (“Catalyst”)
announced that the Board of Directors of Catalyst (the “Board”),
has appointed, effective as of September 9, 2021 (the
“Effective Date”), Ms. Jeanne Y. Jew as a Class III
director of Catalyst with a term to expire at the 2024 Annual
Meeting of Stockholders. In connection with the appointment, the
Board approved an increase in the size of the Board, from seven to
eight members, effective as of the Effective Date.
Ms. Jeanne Y. Jew, 58 years old, has served as the Chief
Business Officer of ALX Oncology Holdings Inc., a publicly traded
company, since August 2020. Prior to joining ALX, she served as
Senior Vice President, Business Development of Paratek
Pharmaceuticals from July 2015 to March 2020. Previously,
Ms. Jew served as Senior Vice President, Business Development
for KaloBios Pharmaceuticals for seven years where she led business
development, strategy, and market planning. Ms. Jew was Vice
President, Corporate and Commercial Development at Onyx
Pharmaceuticals from 2002 to 2007. Ms. Jew held business
development positions at Coulter Pharmaceutical and became Vice
President, Business Development following the acquisition of
Coulter Pharmaceutical by Corixa Corporation. Earlier in her
career, Ms. Jew also held business development positions at
Scios, Inc. and Genentech, Inc. Ms. Jew holds a B.A.in
Psychology from Wesleyan University and an M.B.A. from Cornell
University. The Board believes that Ms. Jew is qualified to
serve on the Board due to her significant experience in the
There are no family relationships between Ms. Jew and any of
Catalyst’s directors or executive officers. In addition, there are
no transactions between Catalyst and Ms. Jew that are subject
to disclosure under Item 404(a) of Regulation S-K.
Ms. Jew will receive cash and equity compensation in
accordance with Catalyst’s current compensation practices for
non-employee directors. She
will also enter into an indemnification agreement with Catalyst
consistent with the form agreement executed with each of Catalyst’s
A copy of the press release announcing the appointment is attached
hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.